Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
Delayed Quote. Delayed Nasdaq - 07/14 04:00:00 pm
26.21 USD   +2.30%
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/05Correction to Poor Performance of Health-Care Stocks Article
DJ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Inovio Pharmaceuticals, In
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Number of employees : 194 people.
Sales per Business
2019
USD (in Million)%
Collaborative Research and Development Arrangements3.6488.4%
Grants and Miscellaneous0.2385.8%
Collaborative Research and Development Arrangements with Affiliated Entities0.2365.7%
Grants and Miscellaneous from Affiliated Entity0.0020%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States30.48100%4.11100% -86.51%
Managers
NameAgeSinceTitle
J. Joseph Kim, Dr.502009President, Chief Executive Officer & Director
Simon X. Benito742019Chairman
Jacqueline E. Shea, Dr.532019Chief Operating Officer & Executive Vice President
Peter D. Kies552002Chief Financial & Accounting Officer
Laurent M. Humeau, Dr.522018Chief Scientific Officer
Kate E. Broderick--Senior Vice President-Research & Development
Mammen P. Mammen, Dr.552020Senior Vice President-Clinical Development
David B. Weiner, Dr.632016Director
Wendy L. Yarno642017Independent Director
Lota S. Zoth592019Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 158,096,451 154,176,818 97.5% 0 0.0% 97.5%
Stock B 0 1,091 0 0.0% 1,068 97.9%
Shareholders
NameEquities%
The Vanguard Group, Inc. 5,363,580 3.39%
Wasatch Advisors, Inc. 3,600,798 2.28%
BlackRock Fund Advisors 3,544,772 2.24%
VHCP Management LLC 2,900,000 1.83%
Nikko Asset Management Americas, Inc. 2,713,984 1.72%
Nikko Asset Management Co., Ltd. 2,713,984 1.72%
J. Joseph Kim 2,211,686 1.40%
SSgA Funds Management, Inc. 1,735,565 1.10%
Millennium Management LLC 1,691,661 1.07%
Geode Capital Management LLC 1,684,463 1.07%
Holdings
NameEquities%Valuation
GeneOne Life Science, Inc. (A011000) 2,012,8924.51%17,228,524 USD
Company contact information
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462-1111

Phone : +1.267.440.4200
Fax : +1.267.440.4242
Web : http://www.inovio.com